Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage

作     者：Inga Nehlmeier Amy Kempf Prerna Arora Anne Cossmann Alexandra Dopfer-Jablonka Metodi V.Stankov Sebastian R.Schulz Hans-Martin Jäck Georg M.N.Behrens Stefan Pöhlmann Markus Hoffmann 

作者机构：Infection Biology UnitGerman Primate Center—Leibniz Institute for Primate ResearchKellnerweg 437077GöttingenGermany Faculty of Biology and PsychologyGeorg-August-University GöttingenWilhelmsplatz 137073GöttingenGermany Department of Rheumatology and ImmunologyHannover Medical SchoolCarl-Neuberg-Straße 130625HannoverGermany German Centre for Infection Research(DZIF)Partner Site Hannover-BraunschweigCarl-Neuberg-Straße 130625HannoverGermany Division of Molecular ImmunologyDepartment of Internal Medicine 3Friedrich-Alexander University of Erlangen-NürnbergGlückstraße 691054ErlangenGermany Centre for Individualized Infection Medicine(CiiM)Feodor-Lynen-Straße 730625HannoverGermany 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2023年第20卷第8期

页      面：969-971页

核心收录：

学科分类：1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基　　金：SP acknowledges funding by the EU project UNDINE(grant agreement number 101057100) the Ministry for Science and Culture of Lower Saxony(Niedersächsisches Ministerium für Wissenschaft und Kultur,14-76103-184,COFONI Network,including projects 7FF22,6FF22,10FF22) the German Research Foundation(Deutsche Forschungsgemeinschaft,DFG,PO 716/11-1) H-MJ received funding from BMBF(01KI2043,NaFoUniMedCovid19-COVIM:01KX2021) Bavarian State Ministry for Science and the Arts(Bayerisches Staatsministerium für Wissenschaft und Kunst)and DFG through the research training groups RTG1660 and TRR130,the Bayerische Forschungsstiftung(Project CORAd)and the Kastner Foundation.GMNB acknowledges funding by the German Centre for Infection Research(Deutsches Zentrum für Infektionsforschung,DZIF grant no 80018019238) Further,GMNB and AD-J acknowledge funding by a European Regional Development Fund(Defeat Corona,ZW7-8515131). 

主　　题：lineage neutral spite 

摘      要：Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in India in early 2023, resulting in XBB.1.16 being the dominating SARS-CoV-2 lineage in India today. Since a similar trend may also take place in other countries and information on the biological properties of the XBB.1.16 lineage is scarce, we conducted a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage with respect to its ability to enter cells and evade neutralisation by antibodies.